Biomedicines Inc. Announces Name Change To Intarcia Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 27 /PRNewswire/ -- BioMedicines, Inc., a leading developer of therapies for patients with cancer, immunological, and infectious diseases, announced today that it has changed its name to Intarcia Therapeutics, Inc.
Commenting on the new corporate name, Intarcia Therapeutics' CEO, Alice Leung said, "During the Renaissance, Italian artisans created inlaid mosaics out of various types of hardwoods -- this art form is called Intarsia. We think this is evocative of the way we redirect development of drugs and biologics. By bringing together different knowledge and technologies we hope to create new, meaningful, and differentiated therapies."
Intarcia Therapeutics Inc, a privately held pharmaceutical company, is developing therapies for the treatment of cancer, immunological, and infectious diseases. The company specializes in redirecting the development of drugs to new indications which meet significant unmet medical needs. The company has agreements with ALZA Corporation, Boehringer Ingelheim, Chiron, Pfizer and Schering AG. Intarcia Therapeutics is headquartered in Emeryville, California. More information about the company is available at http://www.intarcia.com/.Intarcia Therapeutics, Inc.
CONTACT: James Ahlers, CFO of Intarcia Therapeutics, +1-510-652-2600,ext. 235
Web site: http://www.intarcia.com/